Received: 24 November 2020
Accepted: 25 February 2021
First Online: 10 March 2021
: Research was approved by the Royal Veterinary College Clinical Research Ethical Review Board (URN M2015 0053). Owners provided informed consent for all procedures undertaken based on the medical needs of their dog. Owners of dogs provided informed consent for their dog’s data to be used for research purposes.
: HV: Served as contract researcher for: Nestle 2012–2014 and 2017–2019 - dietary modification of epilepsy in dogs; Desitin Pharma, 2012 - the role of levetiracetam in a referral hospital; industrial Funding 2014–2015 - investigating the effects of imepitoin behavioural, physiologic and owner reported indicators of anxiety in dogs treated for idiopathic epilepsy. Received competitive research grants for: RCVS pump primer grant 2010–2013 - pharmacometabonomic profiling of epileptic dogs; Waltham Foundation 2011–2014 - determination of plasma omega-3 fatty acid status in dogs with primary epilepsy and relationship to antiepileptic drug metabolism; CASE BBSRC PhD studentship 2012–2016 - metabolic profiling of epilepsy in dogs; American Kennel Club American Health Foundation, 2016–2018 - Investigating the Effect of a Ketogenic Medium Chain Triglycerides Supplement on the treatment of Canine Idiopathic Epilepsy and its behavioural comorbidities; BBSRC 2017–2020 - Investigating the relationship between epilepsy, drug-resistance and affective disorders in the domestic dog BB/P001874/1.RMAP: Received industrial funding as a co-applicant from Boehringer Ingelheim (2014–15; Investigating the effects of imepitoin on behavioural, physiologic and owner-reported indicators of anxiety in dogs treated for idiopathic epilepsy) and Nestle (2017–19; Dietary modification of epilepsy in dogs). Received competitive research grants from the American Kennel Club (2016–18; Investigating the effect of a ketogenic medium chain triglycerides supplement on the treatment of canine idiopathic epilepsy and its behavioural comorbidities); BBSRC 2017–20; Investigating the relationship between epilepsy, drug-resistance and affective disorders in the domestic dog; BB/P001874/1 and 2017–2020; Comorbidity and characteristics of canine neurodevelopmental disorders and their impact on animal welfare; BB/P 010881/1.CR: Served as a paid consultant for Boehringer Ingelheim in 2014.FW, AC and AT declare that they have no competing interests.